DEVELOPMENT OF A PROTOTYPE POINT-OF-CARE LATERAL FLOW ASSAY TEST SYSTEM FOR MEASURING BLOOD OR PLASMA LEVELS OF CTHRC1 PROTEIN, A NEW BIOMARKER FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS.
Loading...
Date
2024
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Nazarbayev University School of Medicine
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by
proliferative synovitis and inflammatory arthritis accompanied by erosions. RA affects
symmetrically peripheral joints multiple times and often leads to disability. Early diagnosis and
appropriate treatment are essential for the management of RA. This in turn will help to minimize
irreversible changes in synovial joints and to achieve remission or low disease activity.
Despite the existing biomarkers, such as rheumatoid factor (RF) and anti-citrullinated antibodies
(ACPAs), approximately 20-30% of patients are negative for these markers even with the onset of
RA and the development of erosions. Collagen triple helix repeat-containing 1 protein (CTHRC1)
serves as a secreted modulator of Wnt signaling, plays a crucial role in joint remodeling
regulation, and facilitates cell proliferation and migration. CTHRC1 was previously identified as
a highly sensitive and specific blood-based biomarker for RA that can enable the differential
diagnosis of patients...
Description
Keywords
Type of access: Gated
Citation
Zholdybay, A. (2024). Development of a prototype point-of-care lateral flow assay test system for measuring blood or plasma levels of CTHRC1 protein, a new biomarker for the diagnosis of rheumatoid arthritis. Nazarbayev University School of Medicine